FDA Approves New Medtronic Left-Heart Lead

The Food and Drug Administration has approved the availability of Medtronic’s Attain Ability left-heart lead for use with cardiac resynchronization therapy devices for heart failure patients, according to a Medtronic news release.

Advertisement

Attain Ability has the thinnest lead body of any left-heart lead currently available, which can permit physicians to deliver therapy directly to hard-to-reach areas of the heart.

Attain Ability incorporates insulation material developed by NASA Langley Research Center in Hampton, Va., that was previously evaluated for space applications, high-performance engines and harsh environments. This application marks the first time a NASA-developed material has been used in this kind of implantable medical device.

Read the Medtronic release on the Attain Ability left-heart lead.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.